Tatsuya Yoshida

36PUBLICATIONS
141CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Aug 10, 2026
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

|Jun 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancer.

|Jun 02, 2026
Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.

|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.

|Mar 19, 2026
Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor.

Yukiko Shimoda Igawa, Tatsuya Yoshida, Jun Sato

|Feb 11, 2026
Immune checkpoint inhibitors in nuclear protein in testis carcinoma treatment: evidence of limited clinical benefits from a case series.

Tomoaki Nakamura, Tatsuya Yoshida, Akihiko Yoshida

Pageof 6

Frequent Collaborators

10 joint publications

Hidehito Horinouchi

8 joint publications

Yusuke Okuma

8 joint publications

Noboru Yamamoto

6 joint publications

Yasushi Yatabe